Trial Profile
A study investigating safety and efficacy of Nivolumab in combination with multipeptide vaccine in patients with resected stage IIIC or IV melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Jan 2016
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Cancer vaccine NY-ESO-1; Gp100-MART-1 peptides vaccine; Montanide ISA-51
- Indications Malignant melanoma
- Focus Adverse reactions
- 04 Jan 2016 New trial record